Abstract:The human proteome contains approximately 20,000 proteins, and it is estimated that more than 600 of them are functionally important for various types of cancers, including nearly 400 non-enzyme proteins that are challenging to target by traditional occupancy-driven pharmacology. Recent advances in the development of small-molecule degraders, including molecular glues and heterobifunctional degraders such as proteolysis-targeting chimeras (PROTACs), have made it possible to target many proteins that were previously considered undruggable. In particular, PROTACs form a ternary complex with a hijacked E3 ubiquitin ligase and a target protein, leading to polyubiquitination and degradation of the target protein. The broad applicability of this approach is facilitated by the flexibility of individual E3 ligases to recognize different substrates. The vast majority of the approximately 600 human E3 ligases have not been explored, thus presenting enormous opportunities to develop degraders that target oncoproteins with tissue, tumour and subcellular selectivity. In this Review, we first discuss the molecular basis of targeted protein degradation. We then offer a comprehensive account of the most promising degraders in development as cancer therapies to date. Lastly, we provide an overview of opportunities and challenges in this exciting field.

Targeted Protein Degradation: Principles and Applications of the Proteasome

Targeted Protein Degradation: Principles, Strategies, and Applications

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Proteomics of Proteasome Complexes and Ubiquitinated Proteins

Targeted protein degradation: from small molecules to complex organelles—a Keystone Symposia report

Clinical and Marketed Proteasome Inhibitors for Cancer Treatment

Targeted protein degradation: from mechanisms to clinic

Mechanisms and regulation of substrate degradation by the 26S proteasome

Advancing targeted protein degradation for cancer therapy

Proteasome dysregulation in human cancer: implications for clinical therapies

Targeting the Ubiquitin Pathway for Cancer Treatment

Targeted protein degradation: mechanisms, strategies and application

Localized Proteasomal Degradation: From the Nucleus to Cell Periphery

Proteasome Biology: Chemistry and Bioengineering Insights

Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery

Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions

Targeted protein degradation in drug development: Recent advances and future challenges

Conditional PROTAC: Recent Strategies for Modulating Targeted Protein Degradation

Regulation of Proteasome Activity by (Post-)transcriptional Mechanisms

Targeted Protein Degradation Systems: Controlling Protein Stability Using E3 Ubiquitin Ligases in Eukaryotic Species

Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors